EUCTR2009-013235-38-GB进行中（未招募）1 期
A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110µg indacaterol / 50µg glycopyrrolate) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients eligible for inclusion in this study have to fulfill all of the following criteria:
- •1. Male or female adults aged =40 years, who have signed an Informed Consent orm prior to initiation of any study-related procedure.
- •2. Patients with moderate to severe stable COPD (Stage II or Stage III) according to the [GOLD Guidelines 2008].
- •3. Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten
- •pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day or 20 years etc.)
- •4. Patients with post-bronchodilator FEV1 = 30% and <80% of the predicted normal, and post-bronchodilator FEV1/FVC 0.7 at Visit 2 (Post refers to 1 hour after sequential inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of salbutamol or equivalent dose of albuterol).
- •5. Patients, according to daily electronic diary data between Visit 2 and Visit 3, with a
- •total score of 1 or more on at least 4 of the last 7 days prior to Visit 3.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
- •2. Women of child-bearing potential (WOCBP), defined as all women physiologically
- •capable of becoming pregnant, including women whose career, lifestyle, or sexual
- •orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following
- •definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea OR 6 weeks after surgical bilateral oophorectomy (with or without hysterectomy) OR are
- •using one or more of the acceptable methods of contraception described in the protocol.
- •3. Patients requiring long term oxygen therapy (> 15h a day) on a daily basis for chronic hypoxemia.
- •4. Patients who have had a COPD exacerbation that required treatment with antibiotics or oral steroids or hospitalization in the 6 weeks prior to Visit 1 or between Visit 1 and Visit 3
- •5. Patients who develop a COPD exacerbation during the period between Visits 1 and 3 will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation.
- •6. Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1. Patients who develop an upper or lower tract infection during the screening period up to Visit 3) will not be eligible, but will be permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection.
- •7. Patients with concomitant pulmonary disease, see protocol for examples. e.g., pulmonary tuberculosis (unless
- •8. Patients with lung lobectomy, or lung volume reduction or lung transplantation.
- •9. Patients who, in the judgment of the investigator , have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to)
- •unstable ischemic heart disease, left ventricular failure, history of myocardial
- •infarction, arrhythmia (excluding chronic stable AF)
- •history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of
- •Uncontrolled hypo- or hyperthyroidism, hypokalemia or hyperadrenergic state
- •narrow-angle glaucoma
- •symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to
- •severe renal impairment or urinary retention
- •any condition which might compromise patient safety or compliance, interfere
- •with evaluation, or preclude completion of the study
- •10. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil
- •count > 600/mm3 (at Visit 2), or onset of symptoms prior to age 40 years.
- •11. Patients with eczema, known high IgE levels or known positive skin prick test.
- •12. Patients with allergic rhinitis who use H1 antagonists or intranasal corticosteroids
- •intermittently (treatment with a constant dose is permitted)
- •13. Patients with known history and dia
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)EUCTR2009-013235-38-LTovartis Pharma AG339
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-013235-38-LVovartis Pharma AG339
Unknown
3 期
Efficacy, safety and tolerability of serelaxin when added to standardtherapy in Asian patients with acute heart failure (AHF)CTRI/2016/05/006952ovartis Healthcare Pvt Ltd1,520
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-013235-38-HUovartis Pharma AG339
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the effects ofaliskiren on proteinuria when added to standardized losartan therapy and optimal antihypertensive therapy inpatients with hypertension and Type 2 diabetes mellitus.patients with hypertension, Type 2 DM and proteinuriaMedDRA version: 6.1Level: PTClassification code 10061835EUCTR2004-000895-16-ITOVARTIS FARMA